Method for treating deficiency in hematopoiesis
View Patent ↗Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery.
1. A method for treating a mammal for a deficiency in hematopoiesis, the method comprising:
(a) administering one therapeutically effective dose of IL-12 to a mammal with a deficiency in hematopoiesis in need of ameliorating the deficiency; and
(b) administering chemotherapy to the mammal;
wherein the mammal does not have a solid tumor, and the mammal has a hematopoietic malignancy, and
wherein the dose of IL-12 is less than 500 ng/kg.
2. The method of claim 1 , wherein the mammal is a human.
3. The method of claim 1 , wherein the dose of IL-12 is less than 200 ng/kg.
4. The method of claim 1 , wherein the dose of IL-12 is less than 100 ng/kg.
5. The method of claim 1 , wherein the dose of IL-12 is less than 10 ng/kg.
6. The method of claim 1 , wherein the deficiency is substantially the result of the disease state.
7. The method of claim 1 , wherein the deficiency in hematopoiesis comprises a deficiency in one or more hematopoietic cell types or lineages.
8. The method of claim 1 , wherein the deficiency is ameliorated by the IL-12 facilitated proliferation of one or more types of bone marrow cells.
9. The method of claim 1 , wherein the deficiency is ameliorated by the IL-12 facilitated proliferation of hematopoietic repopulating cells, hematopoietic stem cells or hematopoietic progenitor cells.
10. The method of claim 1 , wherein the deficiency comprises a lymphopenia.
11. The method of claim 1 , wherein the deficiency comprises a myelopenia.
12. The method of claim 1 , wherein the deficiency comprises a leukopenia.
13. The method of claim 12 , wherein the leukopenia is neutropenia.
14. The method of claim 1 , wherein the deficiency comprises erythropenia.
15. The method of claim 1 , wherein the deficiency comprises megakaryopenia.
16. The method of claim 1 , wherein the deficiency comprises a deficiency in platelets.
17. The method of claim 1 , wherein the deficiency comprises a deficiency in monocytes.
18. The method of claim 1 , wherein the deficiency comprises a deficiency in lymphocyctes.
19. The method of claim 1 , wherein the deficiency comprises a deficiency in erythrocytes.
20. The method of claim 1 , wherein the deficiency comprises a deficiency in neutrophils.
21. The method of claim 1 , wherein the deficiency comprises a deficiency in T cells.
22. The method of claim 1 , wherein the deficiency comprises a deficiency in granulocytes.
23. The method of claim 1 , wherein the deficiency comprises a deficiency in dendritic cells.
24. A method for stimulating or enhancing hematopoiesis in a mammal, the method comprising:
(a) administering one therapeutically effective dose of IL-12 to a mammal in need of stimulating or enhancing hematopoiesis; and
(b) administering chemotherapy to the mammal;
wherein: (i) the mammal has a hematopoietic malignancy; (ii) the mammal does not have a solid tumor; and (iii) the dose of IL-12 is less than 500 ng/kg.
25. The method of claim 24 , wherein the dose of IL-12 is less than 200 ng/kg.
26. The method of claim 24 , wherein the dose of IL-12 is less than 100 ng/kg.
27. The method of claim 24 , wherein the dose of IL-12 is less than 10 ng/kg.
28. The method of claim 27 , wherein the stimulation or enhancement of hematopoiesis involves the IL-12 facilitated proliferation of bone marrow cells.
29. The method of claim 24 , wherein the stimulation or enhancement of hematoapoiesis involves the IL-12 facilitated proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells or hematopoietic stem cells.
30. The method of claim 29 , wherein the hematopoietic repopulating cells comprise long-term repopulating cells.
31. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising lymphopenia.
32. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising myelopenia.
33. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising leukopenia.
34. The method of claim 33 , wherein the leukopenia is neutropenia.
35. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising a erythropenia.
36. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising megakaryopenia.
37. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising a deficiency in platelets.
38. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising a deficiency in monocytes.
39. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising a deficiency in lymphocyctes.
40. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising a deficiency in erythrocytes.
41. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising a deficiency in neutrophils.
42. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising a deficiency in T cells.
43. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising a deficiency in granulocytes.
44. The method of claim 24 , wherein the mammal has a hematopoietic deficiency comprising a deficiency in dendritic cells.